Enzene Biosciences Profile
Key Indicators
- Authorised Capital ₹ 60.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 51.31 Cr
as on 24-10-2024
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 201.12 Cr
as on 24-10-2024
- Satisfied Charges ₹ 94.20 Cr
as on 24-10-2024
- Revenue 68.55%
(FY 2023)
- Profit 75.25%
(FY 2023)
- Ebitda 37.24%
(FY 2023)
- Net Worth 155.35%
(FY 2023)
- Total Assets 117.12%
(FY 2023)
About Enzene Biosciences
The Corporate was formerly known as Enzene Biosciences Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 60.00 Cr and a paid-up capital of Rs 51.31 Cr.
The company currently has active open charges totaling ₹201.12 Cr. The company has closed loans amounting to ₹94.20 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Enzene Biosciences Limited India are Yogita Hanamshet as Company Secretary, Himanshu Gadgil as Ceo, and Viral Shah as Cfo. Basudeo Singh, Sandeep Singh, Amit Ghare, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24232PN2006PLC165610
- Company No.
165610
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Aug 2006
- Date of AGM
08 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Enzene Biosciences Limited offer?
Enzene Biosciences Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Dietary Supplements, Pharmaceutical Medicine.
Who are the key members and board of directors at Enzene Biosciences?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Yogita Hanamshet | Company Secretary | 15-May-2024 | Current |
| Himanshu Gadgil | CEO | 02-Feb-2022 | Current |
| Viral Shah | CFO | 31-Oct-2018 | Current |
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sangeeta Singh  | Director | 02-Aug-2022 | Current |
| Sandeep Singh | Director | 20-Oct-2011 | Current |
| Prem Pavoor | Director | 30-Jan-2023 | Current |
| Basudeo Singh | Director | 20-Oct-2011 | Current |
| Amit Ghare | Director | 20-Oct-2011 | Current |
| Sudha Ravi | Director | 09-Feb-2017 | Current |
Financial Performance and Corporate Structure Insights of Enzene Biosciences.
Enzene Biosciences Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 68.55% increase. The company also saw a substantial improvement in profitability, with a 75.25% increase in profit. The company's net worth Soared by an impressive increase of 155.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Enzene Biosciences?
In 2023, Enzene Biosciences had a promoter holding of 99.76% and a public holding of 0.24%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eight Roads Investment Advisors Private LimitedActive 17 years 5 monthsPrem Pavoor is a mutual person
Alkem Laboratories LimitedActive 51 years 4 monthsBasudeo Singh, Sandeep Singh and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 16 Feb 2024 | ₹80.00 Cr | Open |
Others Creation Date: 16 Dec 2022 | ₹43.75 Cr | Open |
Axis Bank Limited Creation Date: 31 May 2018 | ₹77.12 Cr | Open |
How Many Employees Work at Enzene Biosciences?
Enzene Biosciences has a workforce of 472 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Enzene Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Enzene Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
